Skip to main content

Advertisement

SpringerLink
Log in

Differential Expressions of Cyclin D1 Associated with Better Prognosis of Cancers of Ampulla of Vater

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Periampullary cancers, the incidence of which increases gradually with industrialization, still pose a significant challenge to clinicians and researchers. Specifically, the role of cell-cycle proteins and tumor suppressor genes in these cancers is not yet clear. Recent studies have revealed that genes and proteins related to cell cycle and apoptosis regulation may be involved in pancreatic carcinogenesis.

Methods

Tissue samples were obtained from patients with periampullary cancers who underwent surgery at the National Taiwan University Hospital without receiving previous chemotherapy or radiation therapy. All periampullary cancer tissue samples were examined by a pathologist, who was unaware of the parameters to be investigated. A total of 68 patients with periampullary cancers (29 ampulla of Vater cancers (AVCs) and 39 pancreatic ductal cancers (PDCs), including various stages and histological subtypes, were enrolled. The relevant demographic and clinicopathological information was obtained from medical records.

Results

Cell-cycle proteins, including p16, Rb, cyclin D1, p53, and E2F1, were analyzed by immunohistochemical staining. Here, significant differences were noted between AVCs and PDCs with regard to the expression of cyclin D1. This corresponded to a poor prognosis in PDCs (P < 0.05); AVCs, on the other hand, showed a relatively high survival rate. There is no obvious statistical difference between the 2 groups with regard to the expression of p16, Rb, p53, and E2F1. The study also revealed that cyclin D1 plays different roles in the carcinogenesis of AVCs and PDCs.

Conclusions

The expression of cyclin D1 is more often correlated with prognosis in AVCs than in PDCs, and may serve as a biomarker for the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Sarmiento JM, Nagomey DM, Sarr MG, et al. Periampullary cancers: are there differences? Surg Clin North Am 2001;81:543–555

    Article  CAS  PubMed  Google Scholar 

  2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897–909

    Article  CAS  PubMed  Google Scholar 

  3. Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991;47:148–154

    Article  CAS  PubMed  Google Scholar 

  4. Kim SG, Chan AO, Wu TT, et al. Epigenetic and genetic alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. Gastroenterology 2003;124:1300–1310

    Article  PubMed  Google Scholar 

  5. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156–3163

    CAS  PubMed  Google Scholar 

  6. Howe JR, Klimstra DS, Cordon-Cardo C, et al. K-ras mutation in adenomas and carcinomas of the ampulla of Vater. Clin Cancer Res 1997;3:129–133

    CAS  PubMed  Google Scholar 

  7. Suto T, Habano W, Sugai T, et al. Infrequent microsatellite instability in biliary tract cancer. J Surg Oncol 2001;76:121–126

    Article  CAS  PubMed  Google Scholar 

  8. Sherr CJ. Cancer cell cycles. Science 1996;274:1672–1677

    Article  CAS  PubMed  Google Scholar 

  9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770–1783

    Article  CAS  PubMed  Google Scholar 

  10. Migaldi M, Sgambato A, Garagnani L, et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131–3138

    CAS  PubMed  Google Scholar 

  11. Alle KM, Henshall SM, Field AS, et al. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847–854

    CAS  PubMed  Google Scholar 

  12. Yuan J, Knorr J, Altmannsberger M, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999;189:358–362

    Article  CAS  PubMed  Google Scholar 

  13. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37–43

    CAS  PubMed  Google Scholar 

  14. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 1998;58:4740–4744

    CAS  PubMed  Google Scholar 

  15. Belvedere O, Puglisi F, Di Loreto C, et al. Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. Ann Oncol 2004;15:55–58

    Article  CAS  PubMed  Google Scholar 

  16. Wang CH, Mo LR, Lin RC, et al. A survival predictive model in patients undergoing radical resection of ampullary adenocarcinoma. Hepatogastroenterology 2004;51:1495–1499

    PubMed  Google Scholar 

  17. Memon MA, Shiwani MH, Anwer S. Carcinoma of the ampulla of Vater: results of surgical treatment of a single center. Hepatogastroenterology 2004;51:1275–1277

    PubMed  Google Scholar 

  18. De Castro SM, Kuhlmann KF, van Heek NT, et al. Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 2004;8:775–784; discussion 784

    Article  PubMed  Google Scholar 

  19. Han S, Park K, Bae BN, et al. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 2003;10:141–144

    CAS  PubMed  Google Scholar 

  20. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg 2001;386:163–171

    Article  CAS  PubMed  Google Scholar 

  21. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634–1637

    CAS  PubMed  Google Scholar 

  22. Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194–197

    Article  CAS  PubMed  Google Scholar 

  23. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469–474

    Article  CAS  PubMed  Google Scholar 

  24. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531–4542

    Article  CAS  PubMed  Google Scholar 

  25. Yamazaki K, Hanami K, Nagao T, et al. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mol Pathol 2003;56:336–341

    Article  CAS  PubMed  Google Scholar 

  26. Liu SC, Zhang SY, Babb JS, et al. Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2001;10:455–459

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan, South Road, Taipei, Taiwan, ROC

    Ming-Chug Chang MD, Yu-Ting Chang MD & Jaw-Town Lin MD, PhD

  2. Department of Forensic Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, Taiwan, ROC

    Chia-Tung Sun MD

  3. Division of Biostatistics and Bioinformatics, National Health Research Institutes, Miaoli, Taiwan, ROC

    Yen-Feng Chiu PhD

  4. Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, Taiwan, ROC

    Yu-Wen Tien MD, PhD

Authors
  1. Ming-Chug Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Ting Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chia-Tung Sun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yen-Feng Chiu PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jaw-Town Lin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-Wen Tien MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-Wen Tien MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, MC., Chang, YT., Sun, CT. et al. Differential Expressions of Cyclin D1 Associated with Better Prognosis of Cancers of Ampulla of Vater. World J Surg 31, 1136–1142 (2007). https://doi.org/10.1007/s00268-006-0032-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-006-0032-6

Keywords

Search

Navigation